Cadherins, catenins and APC in pleural malignant mesothelioma

Journal of Pathology

Volumn 201, Issue 3, 2003, Pages 355-362

  Abutaily, A S ^a   Collins, J E ^a   Roche, W R ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

catenin; Adenomatous polyposis coli; Cadherins; Malignant mesothelioma; Wnt signalling

Indexed keywords

APC; BETA CATENIN; CADHERIN; CATENIN; CELL ADHESION MOLECULE; DNA; GENE PRODUCT; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE CELL ADHESION MOLECULE; UVOMORULIN; WNT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CLASSIFICATION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; DNA EXTRACTION; EXON; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; MUTATIONAL ANALYSIS; PERITONEUM MESOTHELIOMA; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI; ALPHA CATENIN; BASE SEQUENCE; BETA CATENIN; CADHERINS; CELL ADHESION MOLECULES; CYTOSKELETAL PROTEINS; DNA, NEOPLASM; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MUTATION; PHENOTYPE; PLEURAL NEOPLASMS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 0242643649     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1458     Document Type: Article

References (44)

1. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977; 8: 83-94.
2. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271.
3. Battifora H, McCaughey W. Tumors of the serosal membranes. In Atlas of Tumor Pathology, Sobin LH (ed). Armed Forces Institute of Pathology: Washington, DC, 1995; 17-99.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-65.
5. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma - a critical evaluation of new antibodies. J Clin Pathol 2002; 55: 662-668.
6. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
7. Giarre M, Semenov M, Brown A. Wnt signaling stabilizes the dual-function protein beta-catenin in diverse cell types. Ann N Y Acad Sci 1998; 857: 43-55.
8. Gumbiner B, McCrea P. Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci 1993; 17: 1327-1340.
9. Ozawa M, Baribult H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989; 8: 1711-1717.
10. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995; 92: 3046-3050.
11. Zeng L, Fagotto F, Zhang T, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 1997; 90: 181-192.
12. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homology, conduction, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-599.
13. Rubbinfeld B, Albert E, Porfiri E, et al. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272: 1023-1026.
14. Yost C, Torres M, Miller JR, et al. The axis-inducing activity, stability, and subcellular distribution of beta-catenin are regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-1454.
15. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997; 1332: F127-F147.
16. Clevers H, van de Wetering M. TCF/LEF factors earn their wings. Trends Genet 1997; 13: 485-489.
17. Barth A, Nathke I, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathway. Curr Opin Cell Biol 1997; 9: 683-690.
18. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-642.
19. He TC, Sparks AB, Rago C, et al. Identification of c-myc as a target of the APC pathway. Science 1998; 281: 1509-1512.
20. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
21. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
22. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-TCF signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
23. Iwao K, Miyoshi Y, Nawa G, et al. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res 1999; 90: 205-209.
24. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998; 58: 896-899.
25. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-2523.
26. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
27. Fukuchi T, Sakamoto M, Tausda H, et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
28. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/TCF pathway in colorectal cancer. Cancer Res 1998; 58: 1130-1134.
29. Iwao K, Nakamori S, Kameyama M, et al. Activation of beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998; 58: 1021-1026.
30. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59: 269-273.
31. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutations and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999; 59: 1811-1815.
32. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nature Genet 1999; 21: 410-413.
33. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9: 15-21.
34. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-TCF complex in APC-/-colon carcinoma. Science 1997; 275: 1784-1787.
35. Ninomiya I, Endo Y, Fushida S, et al. Alteration of beta-catenin expression in esophageal squamous-cell carcinoma. Int J Cancer 2000; 85: 757-761.
36. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-1455.
37. Bullions LC, Notterman DA, Chung LS, Levine AJ. Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumour suppressor activities. Mol Cell Biol 1997; 17: 4501-4508.
38. Vanpoucke G, Nollet F, Tejpar S, Cassiman JJ, Van Roy F. The human alphaE-cadherin gene CTNNA1: mutational analysis and rare occurrence of a truncated splice variant. Biochim Biophys Acta 2002; 1574: 262-268.
39. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001; 54: 391-395.
40. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002; 40: 536-546.
41. Polakis P. Mutations in the APC gene and their implications for protein structure and function. Curr Opin Genet Dev 1995; 5: 66-71.
42. Hinoi T, Yamamoto H, Kishida M, et al. Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J Biol Chem 2000; 275: 34 399-34 406.
43. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumour suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997; 57: 4624-4630.
44. Maltzman T, Whittington J, Driggers L, Stephens J, Ahnen D. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997; 18: 2435-2439.